Reuters logo
NIH partners 11 drugmakers to accelerate cancer therapy research
October 12, 2017 / 2:04 PM / 2 months ago

NIH partners 11 drugmakers to accelerate cancer therapy research

Oct 12 (Reuters) - The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body’s immune system to fight cancer.

The five-year public-private research collaboration, called Partnership for Accelerating Cancer Therapies, includes drugmakers AbbVie, Roche Holding AG and Bristol-Myers Squibb.

The new class of immunotherapies, such as Roche’s Tecentriq and Bristol-Myers’ Opdivo, works by enlisting the body’s defenses to fight the tumours.

Merck & Co Inc, whose Keytruda leads the fast-expanding field of immunotherapies, is not involved in the partnership.

Pfizer Inc, Johnson & Johnson, Amgen Inc , Celgene Corp, Gilead Sciences Inc and GlaxoSmithKline Plc are part of the effort, NIH said.

The 11 partners would contribute up to $1 million each year for five years, while NIH would add about $160 million, based on availability of funds.

The partnership will be managed by the Foundation for the National Institutes of Health.

Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below